This filing discloses updated analyst ratings and price targets for Rocket Pharmaceuticals from multiple firms. While some analysts maintained 'buy' ratings, one significantly lowered their price target, and another maintained a 'hold' rating, indicating mixed but generally cautious sentiment.
On November 14, 2026, several Wall Street analysts provided updated coverage for Rocket Pharmaceuticals. While Needham and CCORF maintained 'buy' ratings, Wedbush lowered its price target from $15 to $12, and Leerink Partners maintained a 'hold' rating with a $4 target. This mixed sentiment, particularly the lowered price target from Wedbush, suggests some potential concerns or a more conservative outlook on the company's near-term prospects, which could lead to short-term volatility for RCKT as investors digest these varied opinions. The long-term implications depend on whether the company's fundamentals align more with the bullish or cautious analyst views.